Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants

NCT07646548 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL: Dupilumab coformulated with berahyaluronidase alfa
BIOLOGICAL: Dupilumab

Sponsor

Sanofi

Collaborators

[object Object]